Af­ter mul­ti­ple set­backs, Bris­tol My­ers scut­tles Op­di­vo pro­gram for brain tu­mor pa­tients af­ter fail­ing to pro­long lives

4 weeks ago
R&D
Pharma

The fi­nal hours and days are tick­ing away on a $6B bet as dead­line looms on a sus­pense­ful FDA de­ci­sion

4 weeks ago
Bioregnum

Warp Speed bets $356M to mass man­u­fac­ture a Mer­ck drug for se­vere Covid-19

4 weeks ago
Deals
Coronavirus

FDA slaps a hold on Voy­ager's lead gene ther­a­py over 'M­RI ab­nor­mal­i­ties'

4 weeks ago
Cell/Gene Tx
Regulatory

A neigh­bor­ly vis­it turns in­to a bid­ding war: How Dan Skovron­sky se­cured Eli Lil­ly's lat­est $1B buy

4 weeks ago
Deals

A busy, buzzy Ver­tex finds a high-pro­file part­ner in the RNA-drug­ging world to launch a fresh dis­cov­ery ef­fort

4 weeks ago
Deals

A 'sur­pris­ing' Phase III knocks back As­traZeneca, Am­gen's block­buster asth­ma am­bi­tions

4 weeks ago
R&D

The FDA slaps a hold on uniQure's he­mo­phil­ia B gene ther­a­py as re­searchers ex­plore a case of liv­er can­cer in lat­est set­back for a boom­ing field

4 weeks ago
Regulatory

Go­ing head-to-head with Eylea, Roche touts PhI­II win for bis­pe­cif­ic block­buster con­tender in di­a­bet­ic mac­u­lar ede­ma

4 weeks ago
R&D

Agios piv­ots away from on­col­o­gy, auc­tion­ing off can­cer pipeline for $2B and shift­ing the spot­light in re­struc­tur­ing

4 weeks ago
Deals

It's a big day for Mod­er­na — and the world — as the FDA stamps an EUA on their vac­cine. And there are some im­por­tant lessons to re­mem­ber

4 weeks ago
Bioregnum
Regulatory

FDA un­ex­pect­ed­ly de­lays roxa de­ci­sion, foil­ing Fi­bro­Gen's Feb­ru­ary roll­out plans

4 weeks ago
Regulatory

FDA stiff arms No­var­tis in a sur­prise set­back for their PC­SK9 drug in­clisir­an

5 weeks ago
Regulatory
Manufacturing

Glax­o­SmithK­line makes big down pay­ment on biotech tar­get­ing 'syn­thet­ic vi­a­bil­i­ty' with start­up fund­ing, pipeline deals

5 weeks ago
Financing
Discovery

Mer­ck­'s Roger Perl­mut­ter con­tin­ues spin­ning deals, putting up $1B+ for Janux Ther­a­peu­tics and its T cell en­gagers

5 weeks ago
Deals

Covid-19 roundup: EU opts in­to 80M more Mod­er­na vac­cine dos­es; Boehringer In­gel­heim takes its an­ti­bod­ies in­to the clin­ic

5 weeks ago
Coronavirus

No­var­tis' biotech part­ner ad­mits PhI­II Covid-19 de­feat for stem cell ther­a­py, trig­ger­ing ex­ten­sion of $1.2B+ deal close

5 weeks ago
R&D
Coronavirus

'A prece­dent you might not want to set.' FDA-in­vit­ed ex­pert blasts Mod­er­na un­blind­ing plan as ad­comm gets un­der­way

5 weeks ago
Coronavirus

Glax­o­SmithK­line plumbs the dis­cov­ery field (again), bet­ting up to $815M for the lat­est add-on to its on­col­o­gy pipeline

5 weeks ago
Deals

Build­ing its neu­ro pipeline, No­var­tis antes up $210M cash to buy a biotech part­ner drug­ging 'both fla­vors' of NM­DA

5 weeks ago
Deals

EX­CLU­SIVE: As­traZeneca makes tough un­blind­ing call, grap­pling with a vac­cine roll­out that threat­ens to im­pair their em­bat­tled PhI­II

Last month
Coronavirus

No­var­tis sets eyes on new­ly-ac­quired Alex­ion with break­through tag for rare dis­ease hope­ful ip­ta­co­pan

Last month
Pharma
Regulatory

No­var­tis earns ad­com­m's vote of sup­port in come­back FDA re­view for En­tresto in sought-af­ter heart fail­ure pa­tients

Last month
Pharma
Regulatory

Al­ny­lam trail­blaz­er Bar­ry Greene jumps to the helm of a strug­gling Sage Ther­a­peu­tics. Can he de­liv­er an­oth­er come­back?

Last month
People
First page Previous page 123456 Next page Last page